Search

Mannose 6-phosphate

Mannose 6-phosphate has been used in trials studying the treatment of Wound, Cicatrix, Wound-healing, and Re-epithelialisation.

Carvasept

Glibornuride

Glibornuride is a sulfonylurea-type anti-diabetic drug.

Tesaglitazar

Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development. … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

Barium

Barium is under investigation for the diagnostic of Known or Suspected Abdominal Disease.

ARG098

ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

Varlitinib

Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. … Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.

Placental Mesenchymal Stem Cells

It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells. … It was also found that fetal-side pMSCs express different surface markers.

Glypromate

In December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for

SR-9011

SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues … SR-9011 is a REV-ERB agonist.